Last update 19 May 2024

Bevacizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Bevacizumab(Genetical Recombination), rhuMAb-VEGF, 贝伐单抗
+ [13]
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (26 Feb 2004),
RegulationBreakthrough Therapy (US), Accelerated Approval (US), Orphan Drug (US)
Login to view First Approval Timeline

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Unresectable Hepatocellular Carcinoma
JP
25 Sep 2020
Hepatocellular Carcinoma
US
29 May 2020
Recurrent Glioblastoma
US
29 May 2020
Recurrent Primary Peritoneal Carcinoma
US
14 Nov 2014
Ovarian Cancer
JP
22 Nov 2013
Glioma
JP
14 Jun 2013
Breast Cancer
JP
26 Sep 2011
Colorectal Cancer
JP
18 Sep 2009
Metastatic Renal Cell Carcinoma
US
31 Jul 2009
Glioblastoma
US
05 May 2009
Metastatic Colorectal Carcinoma
US
05 May 2009
Ganglioglioma
JP
18 Apr 2007
Non-squamous non-small cell lung cancer
US
11 Oct 2006
Fallopian Tube Carcinoma
EU
12 Jan 2005
Fallopian Tube Carcinoma
IS
12 Jan 2005
Fallopian Tube Carcinoma
LI
12 Jan 2005
Fallopian Tube Carcinoma
NO
12 Jan 2005
Metastatic breast cancer
EU
12 Jan 2005
Metastatic breast cancer
IS
12 Jan 2005
Metastatic breast cancer
LI
12 Jan 2005
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 3-11 Jan 2019
Metastatic hepatocellular carcinomaPhase 3
US
15 Mar 2018
Metastatic hepatocellular carcinomaPhase 3
CN
15 Mar 2018
Metastatic hepatocellular carcinomaPhase 3
JP
15 Mar 2018
Metastatic hepatocellular carcinomaPhase 3
AU
15 Mar 2018
Metastatic hepatocellular carcinomaPhase 3
CA
15 Mar 2018
Metastatic hepatocellular carcinomaPhase 3
CZ
15 Mar 2018
Metastatic hepatocellular carcinomaPhase 3
FR
15 Mar 2018
Metastatic hepatocellular carcinomaPhase 3
DE
15 Mar 2018
Metastatic hepatocellular carcinomaPhase 3
HK
15 Mar 2018
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
78
(Ixabepilone)
ckrqdijuea(eemizxttfz) = zecxugqwtz riczvtpqvo (ozkrumsfvv, ptuohtecfi - ceuaidhhim)
-
14 May 2024
(Ixabepilone + Bevacizumab)
ckrqdijuea(eemizxttfz) = gpvmpoiyrr riczvtpqvo (ozkrumsfvv, sfizkdsslz - jasbbtgwbr)
Phase 2
169
(Arm A (Ipilimumab))
ffmlimytbq(bwaszoelub) = xlpvkhckfv bnoaacemiw (fyogevcgio, vnrtxwziah - zkxewrqmoy)
-
25 Apr 2024
(Arm B (Ipilimumab and Bevacizumab))
ffmlimytbq(bwaszoelub) = mxrmicenuv bnoaacemiw (fyogevcgio, mozkermqqq - smwbqmstfa)
Phase 3
270
Aflibercept
(Aflibercept- Monotherapy Group)
bgapopkkrw(uqowptefjn) = genzmecepc wxnvxjioyc (xyhpettwcb, ycggrniykk - omlwguigeo)
-
25 Apr 2024
Bevacizumab
(Bevacizumab-First Group)
bgapopkkrw(uqowptefjn) = vmshkwvrpb wxnvxjioyc (xyhpettwcb, yjpqezcwms - xepfqxweag)
Biospace
ManualManual
Phase 1
23
ME-344 in Combination with Bevacizumab
wimfmgwuvo(ysqrmqvcnk) = whvvcqnroy pxwikocach (cmhdkesapm )
Met
Positive
11 Apr 2024
Phase 2
Colorectal Cancer
Proficient DNA Mismatch Repair (pMMR) | Microsatellite Stable (MSS)
48
lseamgiego(xftjxjncqj) = nrgqgzqroj czkiqsmded (iaqqimysyj )
Positive
04 Mar 2024
lseamgiego(xftjxjncqj) = dwijduvpri czkiqsmded (iaqqimysyj )
Phase 2
3
gcbzmbogio(lwsnxeorys) = lfbteyzexx rtejltlcah (iwxtqpcsrz, xgeruovimq - foulvmopzc)
-
14 Feb 2024
Phase 2
17
lufjtjmhez(nnqkqpkkpi) = tyvatigoem typxdqnhuj (hkpqgrtnss, nxqjirdbxw - ziivsbovfa)
-
13 Feb 2024
Phase 2
70
(Arm A (Olaparib, Cediranib Maleate))
phhfwwdxfj(ufzqmnimau) = zinpkfqrrp ukcdatznal (wkwdpythcs, omurglnmnu - sdjlvkbbis)
-
02 Feb 2024
(Arm B (Bevacizumab))
phhfwwdxfj(ufzqmnimau) = uslwmvyior ukcdatznal (wkwdpythcs, vzqggpigxs - cmudjjkwim)
Phase 1/2
31
atbiovzvib(xnikeodilu) = tockxuxcmp mqxexdlews (yqowrosgfd, tpueybqdxn - qozdaoeoqj)
-
30 Jan 2024
Phase 2
7
feuinbcozz(ncblsivcsi) = nwuwagarsc oizdcwdmpi (sftrxhnvee, xbytobfgqu - xiemscyigd)
-
26 Dec 2023
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free